Preclinical study of a new (177)Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells

OBJECTIVE(S): Somatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years. The better biomedical properties of radioantagonists as higher tumor uptake make these radioligands more attractive than agonists...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Asia Ocean J Nucl Med Biol
Autors principals: Behnammanesh, Hossein, Erfani, Mostafa, Hajiramezanali, Maliheh, Jokar, Safura, Geramifar, Parham, Sabzevari, Omid, Amini, Mohsen, Mazidi, Seyed Mohammad, Beiki, Davood
Format: Artigo
Idioma:Inglês
Publicat: Mashhad University of Medical Sciences 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7354249/
https://ncbi.nlm.nih.gov/pubmed/32714998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22038/AOJNMB.2020.44432.1299
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars